{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:49Z","timestamp":1793145289480,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed\/refractory cHL after brentuximab vedotin\/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received \u22653 previous lines of systemic therapy (or \u22652 if ineligible for hematopoietic stem cell transplant). Patients received 45 \u03bcg\/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 \u03bcg\/kg IV once every 3 weeks for \u22641 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barr\u00e9\u2013type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015600","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T20:36:03Z","timestamp":1755203763000},"page":"6205-6217","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"3IRCCS Azienda Ospedaliero-Universit\u00e0 di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"4Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"5NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"6Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"7Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione \u201cG. Pascale,\u201d Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"8Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"10Division of Oncology, Siteman Cancer Center, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bence-Bruckler","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Division of Hematology, Ottawa Health Research Institute, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"13Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"15Division of Medical Oncology, Centre for Lymphoid Cancer BC Cancer, BC Cancer and University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"16Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Ren\u00e9-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"18Department of Hematology, University Hospital F Mitterrand, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"19Lymphoma Division, Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[{"name":"20Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"22Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-4160","authenticated-orcid":false,"given":"Sunil","family":"Iyengar","sequence":"additional","affiliation":[{"name":"23Department of Haematology, Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Szomor","sequence":"additional","affiliation":[{"name":"24Division of Hematology, 1st Department of Internal Medicine, Faculty of Medicine, University of P\u00e9cs, P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-2448","authenticated-orcid":false,"given":"William","family":"Townsend","sequence":"additional","affiliation":[{"name":"25Department of Haematology, University College London Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"26Hematology Department, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Dyczkowski","sequence":"additional","affiliation":[{"name":"27ADC Therapeutics SA, \u00c9palinges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Havenith","sequence":"additional","affiliation":[{"name":"28ADC Therapeutics United Kingdom Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Toukam","sequence":"additional","affiliation":[{"name":"29ADC Therapeutics America, Inc, Murray Hill, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafino","family":"Pantano","sequence":"additional","affiliation":[{"name":"27ADC Therapeutics SA, \u00c9palinges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-7760","authenticated-orcid":false,"given":"Hans G.","family":"Cruz","sequence":"additional","affiliation":[{"name":"27ADC Therapeutics SA, \u00c9palinges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"29ADC Therapeutics America, Inc, Murray Hill, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Negievich","sequence":"additional","affiliation":[{"name":"27ADC Therapeutics SA, \u00c9palinges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lucero","sequence":"additional","affiliation":[{"name":"29ADC Therapeutics America, Inc, Murray Hill, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wuerthner","sequence":"additional","affiliation":[{"name":"27ADC Therapeutics SA, \u00c9palinges, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"30Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2025120911213146000_bib1","unstructured":"National Cancer Institute\n          . Cancer stat facts: Hodgkin lymphoma. Accessed 2 May 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"2025120911213146000_bib2","unstructured":"National Cancer Institute\n          . Cancer stat facts: non-Hodgkin lymphoma. Accessed 2 May 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"2025120911213146000_bib3","unstructured":"European Commission\n          . ECIS - European cancer information system. Accessed 2 May 2024. https:\/\/ecis.jrc.ec.europa.eu."},{"key":"2025120911213146000_bib4","author":"Kaseb","year":"2024"},{"issue":"10","key":"2025120911213146000_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/cancers16101830","article-title":"Advances in Hodgkin lymphoma treatment: from molecular biology to clinical practice","volume":"16","author":"Benevolo Savelli","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"35","key":"2025120911213146000_bib6","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025120911213146000_bib7","doi-asserted-by":"crossref","first-page":"2040620720902911","DOI":"10.1177\/2040620720902911","article-title":"Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"15","key":"2025120911213146000_bib8","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2017-09-772681","article-title":"Management of relapsed\/refractory classical Hodgkin lymphoma in transplant-ineligible patients","volume":"131","author":"Mehta-Shah","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2025120911213146000_bib9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2025120911213146000_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/joim.12582","article-title":"Novel treatment concepts in Hodgkin lymphoma","volume":"281","author":"Glimelius","year":"2017","journal-title":"J Intern Med"},{"issue":"1","key":"2025120911213146000_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/hematology.2021000256","article-title":"Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors","volume":"2021","author":"Epperla","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"2025120911213146000_bib12","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025120911213146000_bib13","doi-asserted-by":"crossref","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"2025120911213146000_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"S2","key":"2025120911213146000_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.61_2629","article-title":"Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT-301, Cami) in relapsed\/refractory (R\/R) classical Hodgkin lymphoma (cHL)","volume":"37","author":"Collins","year":"2019","journal-title":"Hematol Oncol"},{"issue":"27","key":"2025120911213146000_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120911213146000_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"2","key":"2025120911213146000_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/modpathol.2016.176","article-title":"A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2","volume":"30","author":"Jensen","year":"2017","journal-title":"Mod Pathol"},{"issue":"4","key":"2025120911213146000_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"2025120911213146000_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"},{"key":"2025120911213146000_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"2025120911213146000_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/WCO.0000000000000867","article-title":"Central nervous system injury from novel cancer immunotherapies","volume":"33","author":"Winter","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"2025120911213146000_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/014107689408700915","article-title":"Effects of lymphoma on the peripheral nervous system","volume":"87","author":"Hughes","year":"1994","journal-title":"J R Soc Med"},{"key":"2025120911213146000_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/1752-1947-8-455","article-title":"Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barr\u00e9 syndrome: a case report","volume":"8","author":"Hughes","year":"2014","journal-title":"J Med Case Rep"},{"key":"2025120911213146000_bib25","doi-asserted-by":"crossref","first-page":"624578","DOI":"10.1155\/2011\/624578","article-title":"Hodgkin's lymphoma: a review of neurologic complications","volume":"2011","author":"Grimm","year":"2011","journal-title":"Adv Hematol"},{"issue":"10","key":"2025120911213146000_bib26","first-page":"19126","article-title":"Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barr\u00e9 syndrome","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"2025120911213146000_bib27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barr\u00e9 syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6205\/2474549\/blooda_adv-2024-015600-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6205\/2474549\/blooda_adv-2024-015600-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:21:43Z","timestamp":1765297303000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6205\/546723\/Camidanlumab-tesirine-for-relapsed-or-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015600","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,12,9]]}}}